Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Neoplasms × dostarlimab × Clear all

Phase

Phase 1 7 Phase 2 5 Phase 3 1 Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Ovarian Neoplasms 3 Carcinoma, Non-Small-Cell Lung 2 Squamous Cell Carcinoma of Head and Neck 1 Recurrence 1 Rectal Adenocarcinoma with Mismatch-repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H) 1 Neoplasms 1 Neoplasm Metastasis 1 Head and Neck Neoplasms 1 Endometrial Neoplasms 1 Colonic Neoplasms 1

Interventions

Paclitaxel 19 Dexamethasone 16 Bevacizumab 16 Oxaliplatin 14 Docetaxel 14 Capecitabine 12 Gemcitabine 11 Cyclophosphamide 11 Sorafenib 10 Leucovorin 10 Fluorouracil 10 Carboplatin 10 Epoetin Alfa 9 pembrolizumab 8 Pemetrexed 8 Fentanyl 8 venetoclax 7 atezolizumab 7 Rivaroxaban 6 Prednisone 6 Ondansetron 6 Morphine 6 Irinotecan 6 Drug Therapy 6 Doxorubicin 6 Denosumab 6 Cisplatin 6 Tranexamic Acid 5 Sodium Chloride 5 Panitumumab 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03981796 2025-09-03

RUBY

Tesaro, Inc.

Phase 3 Active not recruiting

785 enrolled 2 FDA

Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡